CEL-SCI Announces The Potential Impact On The Clinical Development Of Its Immunotherapy Multikine Resulting From A Recent U.S. FDA Oncologic Drugs Advisory Committee Meeting; Multikine Has Shown ...

Hympavzi is Pfizer's second hemophilia treatment to receive FDA approval this year after the agency greenlit its hemophilia B gene therapy Beqvez in April. Analysts expect sales of Hympavzi to ...

The company said it was not yet established that the vaccine had caused the safety event and it was working with the FDA to resolve the pause. "Our goal is to successfully resolve this matter and ...

The third quarter of 2024 saw a slight pickup in pace for FDA new drug approvals, with a total of 13 (Table 1) beating the 11 in Q2 and 10 in Q1. Interestingly though, the commercial expectations ...